- Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drugRoyalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.Fierce Biotech · 6d ago↗ source
- Celldex ends skin disease program after failing phase 2 testA phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming e…Fierce Biotech · 6d ago↗ source
- Trump pledges new tariffs on generic drugs not made in the USPresident Donald Trump on Tuesday evening said he will impose up to 200% tariffs on generic drugs sold in the US, if companies do not manufacture those medicines in America. Trump said that for the…